ELISA News and Research

RSS

Experts share top tips for cancer prevention

Many forms of cancer are preventable. Although risk factors such as age or genetics cannot be changed, other risk factors for cancer including healthy lifestyle choices are within your control.

30 Jan 2023

Study evaluates SARS-CoV-2-specific antibody response in human milk

In a recent study published in the journal Communications Biology, researchers investigated the effect of the coronavirus disease 2019 (COVID-19) vaccine booster on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies in the milk of lactating women. Additionally, they explored whether the booster-induced antibody response differed from the homologous and heterologous boosting schedule of their primary vaccination.

29 Jan 2023

Pregnancy has no effect on long-term immune response to SARS-CoV-2 mRNA vaccination

The immunologic milieu of pregnancy has no effect on the durability of the anti-S IgG response to COVID-19 vaccination

29 Jan 2023

Researchers report a reduction in hospitalizations and deaths from SARS-CoV-2 infections during the Omicron variant-dominated wave in Malawi

Researchers conducted a serosurvey during the SARS-CoV-2 Omicron wave in Malawi.

23 Jan 2023

Longitudinal assessment of immunoglobulin G antibody responses to messenger ribonucleic acid vaccination doses and breakthrough infections

Researchers evaluated immunoglobulin G (IgG) responses to coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccinations.

20 Jan 2023

Exploring bioinformatics approach for evaluating binding affinities of probable COVID-19 therapeutic decoys

Researchers developed a computational workflow based on molecular dynamic (MD) simulations and artificial neural network (ANN) to assess the SARS-CoV-2 spike (S) protein receptor-binding domain (RBD)-human angiotensin-converting enzyme 2 (hACE2) binding affinities of SARS-CoV-2 variants.

17 Jan 2023

Researchers explore immune responses to mpox infections

In new research, researchers demonstrated that individuals recovering from mpox virus (MPXV) infection have neutralizing antibodies that target MPXV antigens A35R and H3L.

17 Jan 2023

Intranasal mRNA-lipid nanoparticle vaccines elicit significant protection against SARS-CoV-2 in hamsters

Researchers from the United States evaluated the efficacy and immunogenicity of an intranasal messenger ribonucleic acid (mRNA)-lipid nanoparticle (LNP) vaccine against SARS-CoV-2 using a hamster model.

16 Jan 2023

What is the effectiveness of a multivalent exosome-based COVID-19 vaccine?

Researchers assessed the effectiveness of a multivalent exosome-based coronavirus disease 2019 (COVID-19) vaccine.

16 Jan 2023

Discovery of a potential new target for new MPOX or broad pox vaccines

In a recent study posted to the medRxiv* preprint server, researchers in the United Kingdom developed a pooled enzyme-linked immunosorbent (ELISA) assay using mpox (MPX) virus (MPXV) antigens and vaccinia virus (VACV) antigens. They also assessed humoral responses to and identification of antigens of MPXV IIa clade and IIb clade, in comparison to recipients of smallpox vaccines (ACAM2000 and IMVANEX).

12 Jan 2023

Study on the ecology of viruses in urban rodents with special emphasis on SARS-CoV-2

In a recent study posted to the bioRxiv* preprint server, researchers investigated whether commensal rodent pests such as rats and mice, sourced from sewers and urban settings, are exposed to and are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They also investigated viruses present in commensal rodents.

12 Jan 2023

Researchers analyze targets of human T cell recognition against all coronaviruses

Researchers analyzed T cell reactivity against alpha and beta common cold coronaviruses (CoVs) [(CCC)] to inform the development of pan-CoV vaccine concepts.

9 Jan 2023

Does the duration between SARS-CoV-2 infection and vaccination affect immunity?

In a recent study posted to the medRxiv* preprint server, researchers at Oregon Health & Science University assessed the impact of the duration between coronavirus disease 2019 (COVID-19) infection and vaccination on immunity against infection.

8 Jan 2023

Does the immunization order of vaccine types influence the efficacy of heterologous prime-boost vaccination, especially mRNA and protein-based vaccines?

A new study aimed to analyze whether the order of immunization of vaccine types impacted the efficacy of a heterologous prime-boost vaccination strategy.

6 Jan 2023

Seroprevalence study demonstrates vaccination could boost impaired humoral immunity against Omicron BQ.1.1 subvariant

Researchers conducted a multicenter, cross-sectional seroprevalence study in emergency departments of five hospitals in North Rhine-Westphalia, Germany, between August and September 2022. They assessed point seroprevalence and neutralization activity against Wu01, BA.4/5, and BQ.1.1.

5 Jan 2023

What is the global state of SARS-CoV-2 seroprevalence in children?

Researchers conducted a systematic review to assess global pediatric SARS-CoV-2 seroprevalence.

3 Jan 2023

Effects of hybrid immunity on humoral immune response following COVID mRNA vaccination in a cohort of essential and frontline workers

Researchers longitudinally evaluated humoral immune responses to the second and third doses of COVID-19 mRNA vaccines among individuals with and without prior history of SARS-CoV-2 infections.

3 Jan 2023

Hybrid immunity from mRNA vaccines and breakthrough Omicron infections induces stronger immune responses against Omicron BQ.1.1

Researchers evaluated plasma samples from individuals vaccinated with a fourth booster dose of mono- or bivalent mRNA SARS-CoV-2 vaccine to evaluate the recognition and neutralization capacity against the ancestral (D614G) strain and the Omicron BQ.1.1 subvariant.

23 Dec 2022

Plasma GH is a biomarker candidate for predicting outcomes in advanced HCC patients treated with Atezo/Bev

A new research paper was published in Oncotarget's Volume 13 on December 6, 2022, entitled, "Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients."

22 Dec 2022

Characterization of anti-orthopoxvirus antibody response in general population and gay men

Scientists have recently estimated and compared anti-mpox and anti-vaccinia antibodies in gay men and the general population.